Gilead now controls the U.S. HIV pre-exposure prophylaxis market with two separate drugs: Truvada and Descovy, a smaller and safer pill.
Descovy is now approved for HIV PrEP in everyone except people who have vaginal sex, since its efficacy has not been studied in this population; for these patients, Truvada is an approved option.
“Descovy for PrEP provides a new HIV prevention option that matches Truvada’s high efficacy with statistically significant improvements in renal and bone safety, which can be an important consideration as people at risk increasingly use PrEP for longer periods of time,” Daniel O’Day, Gilead’s CEO, said in a statement.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
U.S. FDA approves Gilead's Descovy for HIV preventionThe U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc&...
Leer más »
Karamo Brown's 'Proud' of Jonathan Van Ness After HIV Status Reveal'His visibility is helping so many other people to feel comfortable in who they are.'
Leer más »
HHS Awards $13.5 Million to Accelerate State and Local Planning Efforts for Ending the HIV Epidemic: A Plan for AmericaThe U.S. Department of Health and Human Services (HHS), through the Centers for Disease Control and Prevention (CDC), has awarded $13.5 million to conduct state and local planning and kick off community involvement for the proposed federal initiative, Ending the HIV Epidemic: A Plan for America, which seeks to reduce new HIV infections in America by 90% by 2030.
Leer más »
U.S. FDA approves Gilead's Descovy for HIV preventionThe U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc&...
Leer más »
At Harvard B-School, lessons for impact investorsHarvard Business School is known for guiding the next generation of financial le...
Leer más »
Mustard & Roddy Ricch Inspire Kids to Chase Their Dreams in Luxe 'Ballin' Video
Leer más »